Seeking Alpha

BiotechInvestor...'s  Instablog

BiotechInvestor.com
Send Message
Shane Skinner has invested in biotech companies for almost 20 years and placed over $2.6 million in biotech stock trades in 2013. He has held various financial leadership positions over the past 17 years throughout the United States and Europe including Chief Financial Officer. Shane graduated... More
My blog:
BiotechInvestor.com
  • Daily Dose - Spectrum Pharmaceuticals, OncoGenex Pharmaceuticals 0 comments
    Apr 23, 2014 6:45 PM | about stocks: OGXI, TEVA, SPPI

    The Nasdaq Biotech Index pulled back 1.54% after two strong days of gains. Here are some highlights for the day.

    Spectrum (NASDAQ:SPPI) announced that it's multiple myeloma treatment met it's primary endpoint and the company plans to submit an NDA in the 3rd quarter of this year with an expected PDUFA date in 2015. The drug is an improved form of the chemotherapy drug melphalan. If approved, analysts believe the peak sales of the drug could be as high as $50 million annually. This is another near term potential catalyst for Spectrum on top of it's August 9th PDUFA date for it's lymphoma drug Belinostat. The company already markets four drugs with sales of $155 million in 2013 and a number of other drugs in it's pipeline and partnerships with Biogen, Allergen, Bristol-Myers Squibb and others. With a market cap of $453 million I consider the company to be a great value which is why I hold a long position in the company.

    OncoGenex (NASDAQ:OGXI) announced the company and Teva received the Fast Track designation for it's partnered compound Custirsen in 2nd line castration resistant prostate cancer. The drug already has Fast Track status for the same drug in first line CRPC and lung cancer, all of which are currently in phase 3 trials. I wouldn't too much value on the designation as it's worthless if the drug isn't successful in it's phase 3 pivotal trial. They expect enrollment to be complete in the 2nd line CRPC trial in the 2nd half of this year so I would expect top line results in the middle of 2015. In the meantime, they should report top line results of the first line CRPC any time within the next few months. They already announced the required number of events (deaths) have occured and that they are now analyzing the data so fingers crossed!

    Hope everyone is having a great week and feel free to email or tweet me any questions,

    Shane

    Disclosure: I am long OGXI, SPPI.

    Themes: Biotechnology Stocks: OGXI, TEVA, SPPI
Back To BiotechInvestor.com's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »

Latest Comments


Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.